1. Enhanced antimicrobial stewardship based on rapid phenotypic antimicrobial susceptibility testing for bacteraemia in patients with haematological malignancies: a randomized controlled trial. (January 2021) Authors: Kim, J.-H.; Kim, I.; Kang, C.K.; Jun, K.-I.; Yoo, S.H.; Chun, J.Y.; Jung, J.; Kim, Y.J.; Kim, D.Y.; Jo, H.B.; Kim, D.Y.; Koh, Y.; Shin, D.-Y.; Hong, J.; Kim, N.J.; Yoon, S.-S.; Kim, T.S.; Park, W.B.; Oh, M.-d. Journal: Clinical microbiology and infection Issue: Volume 27:Number 1(2021) Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0332 Normalization of Serum Uric Acid Levels After Allogeneic Hematologic Stem Cell Transplantation. (9th June 2015) Authors: Joo, S.H.; Song, Y.W.; Yoon, S.-S.; Park, J.K. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 545 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM]. (23rd June 2022) Authors: Vannucchi, A.; Mesa, R.; Gerds, A.; Al-Ali, H. K.; Lavie, D.; Kuykendall, A.; Grosicki, S.; Iurlo, A.; Goh, Y. T.; Lazaroiu, M.; Egyed, M.; Fox, M. L.; McLornan, D.; Perkins, A.; Yoon, S.-S.; Gupta, V.; Kiladjian, J.-J.; Donahue, R.; Kawashima, J.; Verstovsek, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 940 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. (23rd June 2022) Authors: Nastoupil, L.; Morschhauser, F.; Scholz, C. W.; Bishton, M.; Yoon, S.-S.; Giri, P.; Wei, M. C.; Knapp, A.; Li, C.-C.; Bottos, A.; Li, H.; Purev, E.; Bartlett, N. L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1015 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION. (23rd June 2022) Authors: Röth, A.; Egyed, M.; Ichikawa, S.; Ito, Y.; Kim, J. S.; Nagy, Z.; Obara, N.; Panse, J.; Schrezenmeier, H.; Sica, S.; Soret, J.; Usuki, K.; Yoon, S.-S.; Benkali, K.; Buri, M.; Lundberg, P.; Patel, H.; Shinomiya, K.; Sreckovic, S.; Nishimura, J.-I. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 724 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P894: A PHASE II TRIAL TO EVALUATE THE EFFICACY OF DARATUMUMAB WITH DCEP IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER BORTEZOMIB BASED TREATMENT. (23rd June 2022) Authors: Byun, J. M.; Min, C.-K.; Kim, K.; Bang, S.-M.; Lee, J.-J.; Kim, J. S.; Yoon, S.-S.; Koh, Y. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 785 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P933: DARATUMUMAB (D) IN COMBINATION WITH VD OR D-RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAPSE AFTER INITIAL THERAPY. (23rd June 2022) Authors: Spencer, A.; Moreau, P.; Mateos, M.-V.; Goldschmidt, H.; Suzuki, K.; Levin, M.-D.; Sonneveld, P.; Yoon, S.-S.; Usmani, S. Z.; Weisel, K.; Reece, D.; Ahmadi, T.; Pei, H.; Garvin Mayo, W.; Gai, X.; Carey, J.; Carson, R.; Dimopoulos, M. A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 823 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) Authors: Delimpasi, S.; Quach, H.; Cavo, M.; Ho, P. J.; Lee, C. H.-S.; Santoro, A.; Schots, R.; Vlummens, P.; Yoon, D. H.; Yoon, S.-S.; Santos, C. D.; Samineni, D.; Huang, J.; Wehrman, K.; Patil, U.; Sheikh, S.; Dimopoulos, M. A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1906 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) Authors: Dekhtiarenko, I.; Lelios, I.; Attig, J.; Sleiman, N.; Lazzaro, D.; Clausen, I.; Gräfe, N.; Helms, H.-J.; Schindler, E.; Belli, S.; Fauti, T.; Eckmann, J.; Umana, P.; Jacob, W.; Schneider, M.; Hasselbalch Riley, C.; Hutchings, M.; Yoon, S.-S.; Koh, Y; Manier, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL. (23rd June 2022) Authors: Hasselbalch Riley, C.; Hutchings, M.; Yoon, S.-S.; Koh, Y.; Manier, S.; Facon, T.; Harrison, S. J.; Er, J.; Volzone, F.; Pinto, A.; Montes, C.; Ocio, E. M.; Alfonso-Pierola, A.; Rodriguez Otero, P.; Offner, F.; Guidetti, A.; Corradini, P.; Titouan, C.; Hulin, C.; Touzeau, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗